New TCR modalities are being assessed as well, such as suicide gene-containing T cells that provide a kill-switch and Vγ9Vδ2 TCR-transduced T cells which recognize uncharacterized tumor antigens in an MHC-independent manner. The gene discussed is HLA-C; the disease is neoplasm.